Old Drugs for New Indications in Cardiovascular Medicine |
| |
| Authors: | Yaron Arbel Wael Abuzeid Robert S Rosenson Alanna Weisman Michael E. Farkouh |
| |
| Affiliation: | 1.Department of Cardiology, Tel Aviv Medical Center, Tel Aviv, affiliated to the Sackler School of Medicine,Tel Aviv University,Tel Aviv,Israel;2.Schulich Heart Centre, Division of Cardiology,Sunnybrook Health Sciences Centre, Ontario, Canada, affiliated with the University of Toronto,Toronto,Canada;3.Mount Sinai Icahn School of Medicine,Mount Sinai Hospital,New York,USA;4.Division of Endocrinology & Metabolism, Department of Medicine,University of Toronto,Toronto,Canada;5.Peter Munk Centre, Heart & Stroke Richard Lewar Centre of Excellence,University of Toronto,Toronto,Canada |
| |
| Abstract: | Inflammation participates in the initiation and progression of atherosclerotic cardiovascular disease, and it is a critical inciting factor leading to acute ischemic events. Evidence has shown that certain anti-inflammatory medications used to treat non-atherosclerotic inflammatory diseases reduce cardiovascular events. This article reviews evidence that commonly used anti-inflammatory therapies (colchicine, allopurinol, methotrexate), reduce cardiovascular events. We discuss potential mechanisms of action, efficacy, and safety of these therapies and propose a clinical trials design to investigate their efficacy. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
